Use the basic search or click on advanced for more search options.

Advanced Search Basic Search Advanced Search



Select publication to see the relevant sections.

Publication Date

    E.g., 2018-10-17
    E.g., 2018-10-17

Archive Search

7 results
6:00 PM, May 22, 2015  |  BC Extra | Top Story

Amgen exits brodalumab collaboration with AZ

brodalumab. AZ will hold rights to brodalumab in all territories excluding certain Asian territories where Kyowa Hakko Kirin
7:14 PM, Sep 08, 2014  |  BC Extra | Top Story

Benralizumab continuing despite Phase IIa COPD miss

eosinophil concentrations. AZ has worldwide rights, excluding Japan and certain Asian countries, to benralizumab from Kyowa Hakko Kirin
5:39 PM, Apr 30, 2013  |  BC Extra | Top Story

Aveo plunges on tivozanib briefing docs

has exclusive ex-Asian rights to the inhibitor of VEGF receptors 1, 2 and 3 from Kyowa Hakko Kirin
5:17 PM, Jan 17, 2013  |  BC Extra | Top Story

Public biotechs raise close to $1B

co-development and commercialization rights outside of Asia. Aveo has exclusive ex-Asian rights to tivozanib from Kyowa Hakko Kirin
4:18 PM, Jan 11, 2013  |  BC Extra | Top Story

ArQule's tivantinib misses in colorectal cancer

proceed with further development of tivantinib in colorectal cancer. Last year, ArQule and Asian partner Kyowa Hakko Kirin
5:27 PM, Oct 02, 2012  |  BC Extra | Top Story

ArQule slides on trial discontinuation

a Phase III trial in HCC by year end or early 2013. In August, partner Kyowa Hakko Kirin
5:31 PM, Dec 29, 2011  |  BC Extra | Top Story

FDA unveils REMS for fentanyl drugs

Onsolis from BioDelivery Sciences International Inc. (NASDAQ:BDSI) and Meda AB (SSE:MEDAA). ProStrakan is part of Kyowa Hakko Kirin